Mallinckrodt plc
Mallinckrodt plc, a global leader in specialty pharmaceuticals, is headquartered in Ireland (IE) and operates extensively across North America and Europe. Founded in 1867, the company has a rich history marked by significant milestones in the development of innovative therapies. Specialising in pain management, autoimmune disorders, and critical care, Mallinckrodt offers a range of unique products, including specialty generics and branded medications. Their commitment to addressing unmet medical needs sets them apart in the competitive pharmaceutical landscape. With a strong market position, Mallinckrodt has achieved notable recognition for its contributions to patient care and has established itself as a trusted name in the industry. The company continues to focus on advancing healthcare solutions that improve the quality of life for patients worldwide.
DitchCarbon Score
How does Mallinckrodt plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mallinckrodt plc's score of 41 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mallinckrodt plc's reported carbon emissions
In 2023, Mallinckrodt plc reported total carbon emissions of approximately 89,052,000 kg CO2e for Scope 1 and 74,164,000 kg CO2e for Scope 2, resulting in a combined total of about 162,999,000 kg CO2e. This data reflects their commitment to transparency in emissions reporting, with no Scope 3 emissions disclosed. The company has set ambitious near-term targets to reduce its Scope 1 and 2 emissions to near zero by 2025. This commitment is part of their broader sustainability strategy aimed at addressing climate change and minimising their environmental impact. In 2022, Mallinckrodt's emissions were slightly higher, with Scope 1 emissions at approximately 89,551,000 kg CO2e and Scope 2 emissions (location-based) at about 82,347,000 kg CO2e, leading to a total of around 171,898,000 kg CO2e. The reduction in emissions from 2022 to 2023 indicates progress towards their climate goals. Mallinckrodt's climate initiatives are not cascaded from a parent company, as they operate independently in this regard. Their focus on reducing emissions aligns with industry standards and reflects a growing commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 89,551,000 | 00,000,000 |
| Scope 2 | 82,347,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mallinckrodt plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
